We’ve got a strike

[CLICK HERE JOIN OUR LIVE TRADING & TRAINING SESSIONS]( Hello investor, We’ve got a strike The United Auto Workers began its strike on Friday against three Detriot carmakers, and Wall Street is keeping eyes on whether the strike would escalate or not. Workers walked out from some plants by Ford Motor, General Motors and Stellantis. The strike is not full-fledged yet. Rather, it is designed to cut production of profitable vehicles while minimizing the damage to the UAW’s strike fund. Factories that produce Bronco SUVs, Chevrolet Colorado pickups and Jeep Wrangler SUVs were selected to walked out on. The UAW said it will walk out on more factories, depending on the progress in its bargaining talks. Stocks didn’t get much hit from the strike, indicating that Wall Street is glad that the strike is contained to a few factories for now. The key will be whether more factories will close and potentially damage carmakers’ profits. - “Stocks could express some degree of relief on Friday that the initial strike outcome wasn’t worse,” Citi’s Italy Michaeli and Justin Barell wrote in a note. - “The pushback to that is that the UAW’s strike strategy — while perhaps not as disruptive as feared at the onset — does potentially signal a lengthier period of production disruption, and the situation of course remains fluid.” Citi’s Italy Michaeli (Photo: Bloomberg) Ian Lyngen at BMO Capital Markets believe that higher wages demanded by the UAW is a sign of wage pressures. GM offered a 20% wage hike, which is a huge jump. Would the Fed Reserve view this as inflationary? We will see whether Fed officials will touch on the strike during its September meeting next week. - “...the overall paradigm of workers demanding persistently higher wages presents another dynamic that will keep rates higher for longer in an effort to continue to moderate labor demand,” said Ian Lyngen at BMO Capital Markets. Economists generally expect the Fed to do one more rate hike this year but leave rates unchanged next week. The conversation is shifting towards when the central bank will begin cutting rates again. Will it be early 2024? Or later? Once again, that’s something that investors will keep an eye for Fed officials’ updated projections next week.  Top Growth Stock With Big Profit Margins Today’s Stock Pick: Inspire Medical Systems ([INSP]() You know that the only thing we love more than compound annual growth is compound quarterly growth. Well, today’s company has grown revenue nearly all y-o-y quarters except for one over the past 23 quarters. (Source: MacroTrends) So how exactly are they doing it? Inspire Medical offers a minimally invasive procedure that treats obstructive sleep apnea. - Obstructive sleep apnea blocks patients’ airways while they’re sleeping. The frequency of airway blockage ranges from hourly to more than a hundred times a night. - This means that people can go through long stretches without any oxygen, increasing chances of strokes or cardiac death. At best, those suffering from sleep apnea report insomnia-like sleep quality. (Source: Inspire Medical Systems) Why does Inspire’s new sleep apnea treatment matter? Let’s say you had sleep apnea. Before Inspire, there were two ways to treat it. - You can have the back of your mouth and top of your throat cut up in a surgery that permanently alters your anatomy. The procedure also takes weeks to recover from. (Source: Inspire Medical Systems) - You can wear one of these masks for 6-8+ hours every night. The masks have to be strapped onto your head so they don’t move. There’s nose-only options if you’re willing to tape or strap your mouth shut. (Source: ResMed) Inspire’s implant takes just two hours to put in place. Patients can return to everyday life mere days later. - The device stimulates the nervous system when airways are obstructed. The device is built on a closed-loop system and has 11-year battery life. (Source: Inspire Medical Systems, Inc. Q2 2021 Investor Presentation) Clinical trials show that the treatment works, with the apnea hypopnea index for the frequency of events dropping by a factor of 3.25-4.72 in the 1-5 years post-treatment. Oxygen desaturation (lack of oxygen) during sleep also goes down by a factor of 3.43-5.52 in the same time period. - Just as importantly, patients who withdrew from the treatment saw more than 80% of the symptoms return. (Source: Inspire Medical Systems) Inspire’s patients report 45% less daytime sleepiness. As an added bonus, 81-90% of patients or their partners report a significant improvement in snoring volume. (Source: Inspire Medical Systems) That’s great, what about going forward? Management expects 47%-50% revenue growth this year. CEO Tim Herbert says that physicians and patients are practically breaking down the doors to get this new sleep apnea treatment. - In the second quarter, we continue to increase our capacity to support the strong demand for Inspire therapy by adding 72 new implanting centers in the U.S., ending the quarter with a total of 1,045 centers. For the remainder of 2023, we continue to expect to activate 52 centers to 56 centers per quarter,” Mr. Herbert told analysts. And when customers demand your product, the margins are fantastic. While Inspire is currently not showing profits, its 83% gross margins point to serious pricing power. (Source: Inspire Medical Systems) Bottom Line: Inspire Medical Systems might have one of the most blatantly obvious moats we’ve seen. When the alternative looks like this: (Source: New York Advanced Center For Specialty Care) But feels like this: (Source: Jared Gray | Facebook) You make 83% gross margins and your growth looks like this: (Source: Inspire Medical Systems) This is simply a must-own stock for your portfolio to own a piece of the breakthrough in sleep apnea that will improve tens of thousands of people’s lives instantly.   [CLICK HERE JOIN OUR LIVE TRADING & TRAINING SESSIONS](     © All Rights Reserved, Trade Alliance If you no longer want to receive these messages, you may [click here]( to unsubscribe.